A Biogen Perspective on Drug Development for Neurological Diseases: The Example of Alzheimer’s Disease

Alfred Sandrock, MD, PhD
EVP, Research and Development
Biogen, Inc.
Disclosures

• Full-time employee of Biogen, Inc., and hold shares in the company
• Board of Directors and Scientific Advisory Board of Disarm Therapeutics, Inc., and hold shares in the company
• Member, Innovation Advisory Board, Partners Healthcare
• Former member (until May, 2020) of the Board of Directors of Neurocrine Biosciences, Inc., and hold shares in the company
• Former member (until Feb, 2020) of the Board of Directors of Praxis Precision Medicines, Inc., and hold shares in the company
Forward-looking statements

- This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, relating to additional results from the Phase 3 clinical studies of aducanumab; the potential clinical effects of aducanumab; the potential benefits, safety, and efficacy of aducanumab; potential regulatory discussions, submissions, and approvals and the timing thereof; clinical development programs, clinical trials, data readouts, and presentations related to aducanumab; the enrollment of any future clinical studies of aducanumab; the treatment of Alzheimer’s disease; the potential of Biogen's commercial business and pipeline programs, including aducanumab; the anticipated benefits and potential of Biogen’s collaboration arrangements with Eisai Co, Ltd; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “possible,” “will,” “would,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later-stage or larger-scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented.

- These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation actual timing and content of submissions to and decisions made by the regulatory authorities regarding aducanumab; regulatory submissions may take longer or be more difficult to complete than expected; regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of Biogen’s drug candidates, including aducanumab; actual timing and enrollment of future studies of aducanumab; the occurrence of adverse safety events and/or unexpected concerns that may arise from additional data or analysis; risks of unexpected costs or delays; the risks of other unexpected hurdles; uncertainty of success in the development and potential commercialization of aducanumab; failure to protect and enforce Biogen's data, intellectual property, and other proprietary rights and uncertainties relating to intellectual property claims and challenges; risks relating to the potential launch of aducanumab, including preparedness of healthcare providers to treat patients, the ability to obtain and maintain adequate reimbursement for aducanumab, and other unexpected difficulties or hurdles; product liability claims; third-party collaboration risks; the direct and indirect impacts of the ongoing COVID-19 pandemic on Biogen’s business, results of operations and financial condition; and the other risks and uncertainties that are described in the Risk Factors section of Biogen's most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Biogen’s expectations in any forward-looking statement. These statements are based on Biogen's current beliefs and expectations and speak only as of the date of this presentation. Biogen does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments, or otherwise.
Legal disclaimer

- Aducanumab is an investigational compound and is not yet approved in any country
- Biogen licensed the worldwide rights to aducanumab from Neurimmune Holding AG in 2007 and is responsible for its development and commercialization
- As of October 22, 2017, Biogen and Eisai are collaborating on the development and commercialization of aducanumab globally
There may have been over-reliance on the predictability of animal models in the drug development process.

In an “animal model of disease”

This may be a better approach for “symptomatic therapies” than for drugs that alter the natural history of disease, i.e., “disease-modifying therapies”
A “human biology” approach to developing drugs for neurological disease

1. Clinical observations, genetics, exploratory research
2. Drug discovery
3. Pharmacology, early clinical development
4. Late clinical development
AD Pathology

Amyloid Plaques (Aβ)

Neuro-fibrillary Tangles (p-tau)
The Human Genetic Basis of the Amyloid Hypothesis

Familial Alzheimer’s disease

• Trisomy 21 (Down’s syndrome)—increases Aβ421 •

• APP missense mutation—increases Aβ deposition2,3 •

• PSEN1, PSEN2 (catalytic subunit of Y-secretase)—increases Aβ42/Aβ40 ratio4,6 •

Sporadic Alzheimer’s disease

• ApoE4—decreases Aβ clearance7,8 •

• A673T mutation in APP—reduces cleavage of APP into Aβ42 by β-secretase9 •

• Increases risk of AD • Decreases risk of AD

Clinical and biomarker changes in dominantly inherited Alzheimer’s disease

Aβ, amyloid beta; CDR-SB, Clinical Dementia Rating Scale – Sum of Boxes; CSF, cerebrospinal fluid.
$\alpha\beta 40$ and $42$ are peptides cleaved from Amyloid Precursor Protein on the cell surface.
Aβ40 and 42 are prone to aggregation

Monomer ↔ Oligomer ↔ Fibril → Amyloid plaque

- Soluble
- Insoluble
- Aggregated

Altered neuronal and synaptic morphology\(^{2,3}\)

Structural and functional disruption of neuronal networks\(^{3-6}\)

Postulated as causative of Alzheimer’s disease\(^{6,7}\)

Aducanumab is a human IgG1 anti-Aβ monoclonal antibody developed by Biogen and Neurimmune

- **Human donor cohorts**
  - Healthy “agers”
  - Individuals with Alzheimer’s disease and unusually slow disease progression
- De-identified human memory B-cell libraries were screened for **antibodies that stained β-amyloid plaques** on brain tissue sections from patients with Alzheimer’s disease and aged plaque-bearing APP transgenic mice
- Selection for antibodies that **recognize aggregated**, but not monomeric, forms of Aβ
- Molecular cloning and recombinant expression within a **human IgG1/kappa antibody frame** were used to produce aducanumab


Aβ, amyloid beta; APP, amyloid precursor protein; CMC, chemistry and manufacturing controls; IgG, immunoglobulin G; Tox, toxicology.
Aducanumab is highly selective for Aβ aggregates

• **Direct comparative studies** with murine analogs of gantenerumab, bapineuzumab and solanezumab demonstrate that aducanumab shows the highest selectivity for Aβ aggregates among all antibodies tested.

• This selectivity is **driven by weak monovalent affinity, fast binding kinetics, and strong avidity** for epitope-rich Aβ oligomers and fibrillary aggregates.

Antibody constructs were engineered with chimeric mlgG2 constant regions for all antibodies and with parental murine variable regions for bapineuzumab (3D6) and solanezumab (m266).


Aβ, amyloid beta.
Aducanumab reduces amyloid plaque in a dose-dependent manner in transgenic mice

DEA and Guanidine are biochemical measures of Aβ

Tg2576 mice were dosed for 6 months with murine chimeric aducanumab analog

6E10 and ThioS are histochemical measures of Aβ

*P<0.05 versus control. Sevigny J et al. Nature. 2016;537:50-56.
DEA, diethylamine; ThioS, thioflavin S.
Aducanumab and BAN2401 are highly selective for aggregated Aβ
**PRIME: study design**

**Population**
- Prodromal Alzheimer's disease or mild Alzheimer's disease dementia
- MMSE ≥20
- Stable concomitant medications
- Positive amyloid PET scan

**Endpoints**
- **Primary endpoint**: safety and tolerability
- **Secondary endpoints**: serum PK, immunogenicity, change in amyloid PET (Week 26)
- **Exploratory endpoints**: included CDR–SB, MMSE, change in amyloid PET (Week 54)

**Randomization**: 3:1 active: placebo within cohorts, fixed-dose cohorts stratified by ApoE ε4 status

**Planned sample size**: 188 patients

**Titration cohort** of ApoE ε4 carriers added after enrollment into fixed-dose arms was complete (planned sample size: 21 aducanumab: 7 placebo)

---


ApoE, apolipoprotein; CDR–SB, Clinical Dementia Rating Scale – Sum of Boxes; MMSE, Mini Mental State Examination; PK, pharmacodynamics; PET, positron emission tomography.
PRIME 12-month analysis: Longitudinal change from baseline in amyloid PET SUVR

Nominal p values: * P<0.05; **P<0.01; ***P<0.001 vs placebo. Analyses based on observed data. ANCOVA for change from baseline with factors of treatment, laboratory ApoE ε4 status (carrier and non-carrier), and baseline composite SUVR. PD analysis population is defined as all randomized patients who received at least 1 dose of study medication and had at least 1 post-baseline assessment of the parameter.

PRIME 12-month analysis: Longitudinal change from baseline in CDR-SB (exploratory endpoint)

CDR-SB is an exploratory endpoint. Analyses based on observed data. ANCOVA for change from baseline with factors of treatment, laboratory ApoE ε4 status (carrier and non-carrier), and baseline CDR-SB.

Efficacy analysis population is defined as all randomized patients who received at least 1 dose of study medication and had at least 1 post-baseline questionnaire assessment.

PRIME 12-month analysis: Longitudinal change from baseline in MMSE (exploratory endpoint)

**Graph Description:**
- **Y-axis:** Adjusted mean change from baseline (±SE)
- **X-axis:** Analysis visit (weeks)
- **Legend:**
  - Placebo: n=45 44 40
  - 1 mg/kg: n=26 26 25
  - 3 mg/kg: n=29 29 26
  - 6 mg/kg: n=28 28 26
  - 10 mg/kg: n=30 29 25
  - Titration: n=21 20 21

**Legend Values:**
- Difference from placebo at Week 52
  - Placebo: 0.47
  - 1 mg/kg: 1.91*
  - 3 mg/kg: 1.70
  - 6 mg/kg: 1.46
  - 10 mg/kg: 0.47
  - Titration: 0.25

**Statistical Notes:**
- *Nominal P<0.05 vs placebo

**Textual Note:**
- **MMSE:** is an exploratory endpoint. Analyses based on observed data. ANCOVA for change from baseline with factors of treatment, laboratory ApoE ε4 status (carrier and non-carrier), and baseline MMSE.
- Efficacy analysis population is defined as all randomized patients who received at least 1 dose of study medication and had at least 1 post-baseline questionnaire assessment.

---

*Nominal P<0.05 vs placebo
Amyloid Related Imaging Abnormalities [ARIA-E]
PRIME 12-month analysis: Dose titration attenuated incidence of ARIA-E versus higher fixed doses

<table>
<thead>
<tr>
<th>Patients with at least 1 post-baseline MRI</th>
<th>Placebo</th>
<th>1 mg/kg</th>
<th>3 mg/kg</th>
<th>6 mg/kg</th>
<th>10 mg/kg</th>
<th>Titration</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARIA-Ea, n/total (%)</td>
<td>0/46</td>
<td>1/31 (3)</td>
<td>2/32 (6)</td>
<td>11/30 (37)</td>
<td>13/32 (41)</td>
<td>8/23 (35)</td>
</tr>
<tr>
<td>ApoE ε4 carriers</td>
<td>0/32</td>
<td>1/19 (5)</td>
<td>1/21 (5)</td>
<td>9/21 (43)</td>
<td>11/20 (55)</td>
<td>8/23 (35)</td>
</tr>
<tr>
<td>ApoE ε4 non-carriers</td>
<td>0/14</td>
<td>0/12</td>
<td>1/11 (9)</td>
<td>2/9 (22)</td>
<td>2/12 (17)</td>
<td>-</td>
</tr>
<tr>
<td>Isolated ARIA-H, n (%)</td>
<td>3/46 (7)</td>
<td>2/31 (5)</td>
<td>3/32 (9)</td>
<td>0/30</td>
<td>2/32 (6)</td>
<td>0/23</td>
</tr>
</tbody>
</table>

Summary of PRIME 12-month results*

- Aducanumab treatment significantly reduced amyloid plaque burden in a dose- and time-dependent manner.
- Aducanumab treatment also reduced clinical decline as measure by the CDR-SB and MMSE in a dose- and time-dependent manner.
- ARIA was the main adverse event associated with Aducanumab.
  - Titration up to 10 mg/kg may reduce incidence of ARIA-E compared with higher fixed dosing based on the ApoE ε4 cohort studied.
- PRIME results supported the study design of the EMERGE and ENGAGE Phase 3 trials, which investigated the clinical efficacy and safety of aducanumab in patients with early stages of Alzheimer’s disease.

*PRIME is a small study and the efficacy endpoints were exploratory. In PRIME, safety and tolerability was the primary endpoint. Viglietta V, et al. J Prev Alz Dis 2016:3:278. Data presented at CTAD 2016. ARIA-E, ARIA due to vasogenic edema; CDR-SB, Clinical Dementia Rating-Sum of Boxes; MMSE, Mini-Mental State Examination.
# Aducanumab Phase 3 studies EMERGE and ENGAGE

<table>
<thead>
<tr>
<th>Studies</th>
<th>Two 18-month, randomized, double-blind, placebo-controlled, Phase 3 studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Geography/sample size</td>
<td>3285 patients at 348 sites in 20 countries</td>
</tr>
</tbody>
</table>
| Population       | ▪ Early Alzheimer’s disease (MCI due to Alzheimer’s disease + mild Alzheimer’s disease dementia)  
                  ▪ MMSE 24-30, CDR-G 0.5, RBANS ≤ 85, with confirmed amyloid pathology |
| Doses            | ▪ Two dosing regimens (low and high) and placebo; randomized 1:1:1          |
| Primary endpoint | ▪ CDR-SB at 18 months                                                     |
| Other endpoints  | ▪ Secondary: MMSE, ADAS-Cog 13, ADCS-ADL-MCI                               
                  ▪ Sub-studies: amyloid PET, tau PET, CSF disease-related biomarkers |

## Countries with active sites included:
Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Italy, Japan, the Netherlands, Poland, Portugal, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States

Summary of aducanumab Phase 3 topline results (1 of 2)

- In the aducanumab Phase 3 trial program, modification of biomarkers of underlying disease pathology was associated with statistically significant slowing of clinical decline
  
  - In the amyloid PET sub-study, there was a dose- and time-dependent reduction in amyloid PET SUVR at Week 78 in both EMERGE and ENGAGE
    
    - The reduction in amyloid PET SUVR in ENGAGE was smaller than the reduction observed in EMERGE
  
  - Data from EMERGE showed a statistically significant advantage of high-dose aducanumab over placebo on the pre-specified primary endpoint, CDR-SB, at Week 78
    
    - A statistically significant slowing of clinical decline was also detected across three secondary endpoints – MMSE, ADAS-Cog13, and ADCS-ADL-MCI
  
- In ENGAGE, aducanumab did not reduce clinical decline
  
  - In a post hoc analysis, data from a subset of patients from ENGAGE with the opportunity to receive 10 mg/kg aducanumab support the positive findings of EMERGE
Summary of aducanumab Phase 3 topline results (2 of 2)

• Results from biomarker sub-studies of downstream biomarkers specific to Alzheimer's disease (tau PET and CSF p-tau) and neurodegeneration (CSF t-tau) further support the clinical findings
  • In EMERGE and ENGAGE, there was a statistically significant reduction in CSF p-tau
  • In EMERGE, there was a numerical reduction in CSF t-tau in both dose groups and in ENGAGE there was a numerical reduction in t-tau in the low dose group
  • In the tau PET sub-study (patients pooled across both studies) there was a statistically significant and dose-dependent reduction in tau PET SUVR in the medial temporal, temporal and frontal regions in patients treated with aducanumab versus placebo
• The most common AEs in EMERGE and ENGAGE were ARIA-E and headache
• A re-dosing study, EMBARK, is currently offering aducanumab to eligible patients who were actively enrolled in the aducanumab clinical studies
• The FDA has accepted regulatory submission for aducanumab under priority review
• Biogen is planning to submit a new drug application for aducanumab in Japan

AE, adverse event; ARIA, amyloid-related imaging abnormalities; ARIA-E, amyloid-related imaging abnormalities due to vasogenic edema; CSF, cerebrospinal fluid; FDA, U.S. Food and Drug Administration; PET, positron emission tomography; SUVR, standardized uptake value ratio.
The example of Aducanumab

"Reverse Translational Medicine" (Neurimmune, Inc.)

1. Human genetics
2. Human pathology
3. Longitudinal observations (imaging, biomarkers)

Aducanumab

Amyloid hypothesis

Amyloid PET imaging
PRIME Phase 1b study

Alzheimer’s disease

CDR-SB, MMSE
PRIME Phase 1b study
Confirmation: Phase 3 trials

CDR-SB, Clinical Dementia Rating Scale – Sum of Boxes; MMSE, Mini Mental State Examination; PET, positron emission tomography.
Conclusions

We are in an era of redefining neurologic diseases in actionable terms
• Genetics, targets within causal biological pathways

We have advanced the measurement of disease progression
• To obtain early POC
• To obtain registration

We have tools that decrease the risk of drug development in neurology
• Identify patient early in their disease
• Identify subpopulations of patients
• With biomarkers, measure target engagement or desired biological response

We have new therapeutic approaches that enable rapid R&D from gene to drug
• Antisense oligonucleotides
• Monoclonal antibodies
Acknowledgements

My colleagues at Biogen, Eisai, and Neurimmune

All the advisors, investigators, patients, and family members who participated in the aducanumab studies